SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
1-Year Return
71.55%
This Quarter Return
+18.55%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$444M
AUM Growth
+$38.7M
(+9.5%)
Cap. Flow
+$6.85M
Cap. Flow
% of AUM
1.54%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
80
New
13
Increased
27
Reduced
18
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$15.2M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$11.9M |
| 3 |
Vaxcyte
PCVX
|
$6.63M |
| 4 |
Protagonist Therapeutics
PTGX
|
$6.6M |
| 5 |
Veracyte
VCYT
|
$6.41M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$16.6M |
| 2 |
Nuvalent
NUVL
|
$9.64M |
| 3 |
Celldex Therapeutics
CLDX
|
$7.81M |
| 4 |
Corbus Pharmaceuticals
CRBP
|
$7.81M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$2.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ADC Therapeutics
ADCT
$366M
| $5.65M | 1.27% |
1,795,080
+26,310
| +1% | +$82.9K |
|
27
Gossamer Bio
GOSS
$562M
| $5.57M | 1.25% |
5,645,352
+145,352
| +3% | +$143K |
|
28
Olema Pharmaceuticals
OLMA
$430M
| $5.43M | 1.22% |
455,082
-91,781
| -17% | -$1.1M |
|
|
BBOT
29
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$789M
| $5.36M | 1.2% |
513,369
+13,369
| +3% | +$140K |
|
|
ABVX
30
Abivax
ABVX
$6.44B
| $5.32M | 1.19% |
461,660
+5,860
| +1% | +$67.5K |
|
31
Wave Life Sciences
WVE
$1.28B
| $5.15M | 1.16% |
627,552
+132,081
| +27% | +$1.08M |
|
32
Disc Medicine
IRON
$2.09B
| $5.1M | 1.15% |
103,862
+2,675
| +3% | +$131K |
|
33
Biohaven
BHVN
$1.7B
| $4.98M | 1.12% |
99,566
-434
| -0.4% | -$21.7K |
|
|
34
Celldex Therapeutics
CLDX
$1.51B
| $4.93M | 1.11% |
145,000
-229,910
| -61% | -$7.81M |
|
|
LBPH
35
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $4.14M | 0.93% |
124,353
+1,504
| +1% | +$50.1K |
|
36
Biogen
BIIB
$20.3B
| $3.87M | 0.87% |
19,940
+575
| +3% | +$111K |
|
37
Praxis Precision Medicines
PRAX
$958M
| $3.86M | 0.87% |
67,045
-251
| -0.4% | -$14.4K |
|
38
Modular Medical
MODD
$38.8M
| $3.24M | 0.73% |
1,440,000
+540,000
| +60% | +$1.22M |
|
39
Solid Biosciences
SLDB
$428M
| $3.19M | 0.72% |
457,739
-15,256
| -3% | -$106K |
|
40
BioNTech
BNTX
$24.8B
| $3.1M | 0.7% |
+26,083
| New | +$3.1M |
|
41
Structure Therapeutics
GPCR
$1.12B
| $3.09M | 0.7% |
70,516
| – | – |
|
42
Mersana Therapeutics
MRSN
$34.6M
| $3M | 0.67% |
63,431
-36,592
| -37% | -$1.73M |
|
43
Relay Therapeutics
RLAY
$698M
| $2.97M | 0.67% |
+419,242
| New | +$2.97M |
|
44
TELA Bio
TELA
$62.2M
| $2.85M | 0.64% |
1,124,928
+124,928
| +12% | +$316K |
|
45
Compugen
CGEN
$130M
| $2.72M | 0.61% |
1,501,113
| – | – |
|
46
Cerus
CERS
$253M
| $2.6M | 0.58% |
1,495,329
+29,585
| +2% | +$51.5K |
|
47
Zevra Therapeutics
ZVRA
$496M
| $2.43M | 0.55% |
+350,000
| New | +$2.43M |
|
48
Perspective Therapeutics
CATX
$255M
| $2.24M | 0.5% |
167,986
-92,023
| -35% | -$1.23M |
|
|
BIOA
49
BioAge Labs, Inc. Common Stock
BIOA
$166M
| $2.08M | 0.47% |
+100,000
| New | +$2.08M |
|
50
Unicycive Therapeutics
UNCY
$75.1M
| $1.63M | 0.37% |
+400,000
| New | +$1.63M |
|